Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide
| Autor: | Daniel J. George, Fred Saad, Christopher Michael Pieczonka, Michael Cookson, Daniel Saltzstein, Ronald F. Tutrone, Bruce Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Neal D. Shore |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 40:105-105 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2022.40.6_suppl.105 |
| Popis: | 105 Background: Prostate cancer disproportionately impacts Black men, with a higher incidence and worse outcomes relative to other races (Siegel DA, MMWR Morb Mortal Wkly Rep. 2020;69:1473). In the international phase 3 HERO study, relugolix, the once-daily oral GnRH receptor antagonist, demonstrated superior continuous suppression of testosterone to castrate levels through week 48 compared to leuprolide (96.7% for relugolix vs. 88.8% of men receiving leuprolide; Shore N, NEJM 2020; 382:2187) in men with advanced prostate cancer (APC). To further characterize the results from this trial in black men a subgroup analysis of HERO was undertaken. Methods: HERO was a phase 3 randomized, open-label, study to evaluate relugolix vs. leuprolide in 930 treated men with APC. The subgroup analyzed included all Black men enrolled in the HERO study. Assessments analyzed included sustained testosterone suppression to castrate levels (50% decrease) at day 15 with confirmation at day 29, profound castration rate ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|